menu search

Novartis to present new data across oncology portfolio including kisqali phase iii natalee trial in early breast cancer at asco

Basel, April 26, 2023 — Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual M...

April 26, 2023, 10:21 am

Arrowhead pharmaceuticals shares rise on positive interim trial results

Arrowhead Pharmaceuticals has released positive interim results from its Phase 1/2 study of its investigational therapeutic ARO-RAGE for inflammatory ...

April 25, 2023, 11:07 am

Apellis presents phase 3 functional analyses of syfovre™ (pegcetacoplan injection) for geographic atrophy

Showed visual function and quality-of-life benefits in patients with extrafoveal lesions Slowed the loss of retinal pigmented epithelial and photo...

April 23, 2023, 10:05 pm

Cognition therapeutics to present analysis showing impact of ct1812 on pathways implicated in dry age-related macular degeneration at arvo 2023

NEW YORK, April 19, 2023 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be presenting in vitro results characterizing the role ...

April 19, 2023, 11:30 am

Alaunos therapeutics to participate in upcoming investor conferences in april

HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell ...

March 29, 2023, 5:30 pm

Viking's stock rallies as it announces trial for oral version of obesity drug

Shares of Viking Therapeutics Inc. VKTX, +3.05% soared about 45% in premarket trading on Tuesday after the company said it started a Phase 1 clinical ...

March 28, 2023, 8:19 am

Tonix pharmaceuticals exec presents data on prader-willi syndrome drug at rare disease conference

Tonix Pharmaceuticals (NASDAQ:TNXP) Holding Corp EVP of translation medicine Herbert Harris delivered an oral presentation Thursday at the Rare Diseas...

March 23, 2023, 4:41 pm

Celyad oncology to announce full year 2022 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company...

March 17, 2023, 5:01 pm

Okyo pharma shares soar on news it is gearing up for dry eye disease treatment trial

OKYO Pharma's London-listed shares soared on Friday after the biopharmaceutical company announced it has started a trial process for its dry eye disea...

March 17, 2023, 3:13 pm

Royalty pharma raises fy2023 guidance after $475m pfizer milestone payment

Royalty Pharma plc announced that it is raising its full year 2023 Adjusted Cash Receipts (non-GAAP) guidance to between $2.85 billion and $2.95 bill...

March 15, 2023, 11:42 am

Pfizer wins fda approval for its migraine nasal spray

Pfizer Inc. PFE, -1.65% said Friday the U.S. Food and Drug Administration has approved its migraine nasal spray Zavzpret. The treatment is the first a...

March 10, 2023, 6:54 am

Pharvaris to present in upcoming march investor conferences

ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

March 2, 2023, 6:50 am

Chinook's atrasentan: a promising solution for iga nephropathy?

Chinook is a clinical-stage biopharmaceutical firm that is developing precision medicines for kidney diseases, including treatments for rare, chronic,...

February 13, 2023, 3:02 pm

Pharvaris to present at svb securities global biopharma conference

ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-...

February 8, 2023, 6:50 am

Context therapeutics highlights clinical responses from clinical trial evaluating ona-xr to treat endometrial cancer

Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat ...

February 6, 2023, 8:18 am

Context therapeutics says clinical partner stemline therapeutics receives fda approval for orserdu to treat certain breast cancers

Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Me...

January 31, 2023, 8:33 am

Bluesphere bio appoints erkut bahceci, m.d., as chief medical officer

Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) — Blue...

January 30, 2023, 3:17 pm

Avalon globocare says it has been issued with a us patent for multiple novel qty-code modified cytokine and chemokine protein receptor molecules

Avalon GloboCare Corp (NASDAQ:ALBT) has announced that the US Patent and Trademark Office (USPTO) has issued it with US Patent No. 11,555,060, titled ...

January 17, 2023, 9:13 am

Respirerx pharmaceuticals establishes resolutionrx in australia to advance its cannabinoid program

RespireRx Pharmaceuticals (OTC:RSPI) Inc said that as of January 11, 2023, it has established a new, currently wholly-owned, unlisted public company i...

January 12, 2023, 9:32 am

Hyperkalemia, congestive heart failure, and aldosterone receptor antagonism

Hyperkalemia is a common occurrence in patients with congestive heart failure, particularly when renal failure coexists. The level of renal function i...

January 3, 2023, 8:14 am


Search within

Pages Search Results: